JPMorgan Chase & Co. Purchases 175,019 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

JPMorgan Chase & Co. increased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 108.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 335,741 shares of the biopharmaceutical company's stock after purchasing an additional 175,019 shares during the period. JPMorgan Chase & Co. owned 0.58% of Vanda Pharmaceuticals worth $1,608,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 5,459 shares during the period. Franklin Resources Inc. raised its holdings in Vanda Pharmaceuticals by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 4,449 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Vanda Pharmaceuticals during the 4th quarter worth about $649,000. Barclays PLC lifted its position in Vanda Pharmaceuticals by 128.2% during the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after purchasing an additional 86,677 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Vanda Pharmaceuticals by 2.1% in the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock valued at $1,438,000 after purchasing an additional 6,079 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Performance

VNDA traded up $0.13 during midday trading on Tuesday, reaching $4.43. 458,049 shares of the company were exchanged, compared to its average volume of 768,805. The stock has a market capitalization of $258.34 million, a P/E ratio of -13.84 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a one year low of $3.85 and a one year high of $6.75. The stock's 50-day simple moving average is $4.56 and its 200 day simple moving average is $4.68.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. On average, research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Activity at Vanda Pharmaceuticals

In related news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company's stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. This represents a 0.43 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders bought a total of 32,000 shares of company stock worth $151,180 in the last quarter. Corporate insiders own 8.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on VNDA shares. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, April 1st. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating for the company.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.